Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.
Adult
Anxiety Disorders
/ complications
Colitis, Ulcerative
/ psychology
Crohn Disease
/ psychology
Depressive Disorder, Major
/ complications
Female
Humans
Inflammatory Bowel Diseases
/ psychology
Male
Middle Aged
Prevalence
Risk Factors
Substance-Related Disorders
/ complications
Surveys and Questionnaires
SCID
inflammatory bowel disease
substance use disorders
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
23
11
2019
pubmed:
7
2
2020
medline:
16
11
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort. Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants' sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling. Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17-7.50), male sex (aOR, 2.44; 95% CI, 1.11-5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08-5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01-1.16). One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.
Sections du résumé
BACKGROUND
Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.
METHODS
Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants' sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling.
RESULTS
Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17-7.50), male sex (aOR, 2.44; 95% CI, 1.11-5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08-5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01-1.16).
CONCLUSIONS
One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.
Identifiants
pubmed: 32025740
pii: 5728525
doi: 10.1093/ibd/izaa014
pmc: PMC7737154
doi:
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-64Subventions
Organisme : CIHR
ID : THC-135234
Pays : Canada
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
J Psychosom Res. 2017 Oct;101:17-23
pubmed: 28867419
Am J Gastroenterol. 2014 Oct;109(10):1613-20
pubmed: 25178702
J Clin Psychiatry. 2019 May 28;80(3):
pubmed: 31141319
Neuroepidemiology. 2010 Aug;35(2):83-90
pubmed: 20551692
Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):553-559
pubmed: 29195675
Health Policy. 2018 Mar;122(3):205-209
pubmed: 29429644
Biol Sex Differ. 2012 Jun 07;3(1):14
pubmed: 22676718
Front Neuroendocrinol. 2014 Aug;35(3):272-84
pubmed: 24769267
JMIR Res Protoc. 2018 Jan 17;7(1):e15
pubmed: 29343461
Inflamm Bowel Dis. 2015 Oct;21(10):2341-8
pubmed: 26218145
J Pediatr Gastroenterol Nutr. 2019 Sep;69(3):324-329
pubmed: 30985442
Curr Psychiatry Rep. 2015 Feb;17(2):4
pubmed: 25617040
Arch Gen Psychiatry. 2007 Jul;64(7):830-42
pubmed: 17606817
Curr Psychiatry Rep. 2012 Jun;14(3):176-81
pubmed: 22527871
Gut. 2019 Sep;68(9):1597-1605
pubmed: 30630948
Am J Psychiatry. 2013 Aug;170(8):834-51
pubmed: 23903334
Depress Anxiety. 2018 Sep;35(9):851-860
pubmed: 29999576
Arch Gen Psychiatry. 2011 Aug;68(8):800-7
pubmed: 21810645
Tob Control. 2014 Nov;23(e2):e147-53
pubmed: 24727731
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):99-111
pubmed: 25747923
Am J Addict. 2005 Mar-Apr;14(2):106-23
pubmed: 16019961
Prev Med. 2016 Nov;92:148-159
pubmed: 27196143
Drug Alcohol Depend. 2018 Nov 1;192:316-323
pubmed: 30312893
J Clin Med. 2019 May 10;8(5):
pubmed: 31083476
Arch Gen Psychiatry. 2007 May;64(5):566-76
pubmed: 17485608
Ann Gastroenterol. 2018 Nov-Dec;31(6):649-658
pubmed: 30386114
J Affect Disord. 2019 Mar 15;247:120-124
pubmed: 30660021
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
Clin J Pain. 2013 Aug;29(8):689-95
pubmed: 23835765
Scand J Gastroenterol. 1978;13(7):833-7
pubmed: 364626
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Inflamm Bowel Dis. 2020 Aug 20;26(9):1401-1406
pubmed: 31725152
Drug Alcohol Depend. 2015 Sep 1;154:1-13
pubmed: 26072219
Am J Gastroenterol. 2008 Aug;103(8):1989-97
pubmed: 18796096
Dialogues Clin Neurosci. 2015 Sep;17(3):245-6
pubmed: 26487805
Am J Gastroenterol. 1997 Aug;92(8):1247-52
pubmed: 9260783